{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:34Z","timestamp":1787181934530,"version":"build-2736575974"},"reference-count":23,"publisher":"CSIRO Publishing","issue":"5","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although clinical trials and real-world studies demonstrate the efficacy and tolerability of dolutegravir and lamivudine (DTG\u00a0+\u00a03TC), Australian real-world evidence remains limited despite differences in access to health care and prescribing context. Here, we present the motivations for switching to DTG\/3TC (a fixed-dose, single-tablet regimen) and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective, observational analysis of individuals with HIV with an undetectable viral load (VL; &amp;lt;50\u00a0copies\/mL) who switched to DTG\/3TC during a 24-month inclusion window from 1 December 2020 to 1 December 2022, in nine Australian clinics. Healthcare providers completed an electronic survey using baseline demographics of people with HIV and other clinical information gathered from participant medical records. Data were collected after December 2023 to allow a 12-month follow-up. Primary endpoints were baseline demographics, clinical characteristics, and motivations for switching to DTG\/3TC. Secondary endpoints included virologic outcomes and rates and reasons for DTG\/3TC discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 276 individuals with HIV who switched to DTG\/3TC were included. Most were male (97%) and White (76%), with a median (interquartile range) age of 54 (45\u201361) years. The most common antiretroviral therapy before DTG\/3TC switch was abacavir\/dolutegravir\/lamivudine (54%). The most common reason for switching to DTG\/3TC was clinician preference for two-drug regimen (43%). Most individuals (98%) maintained virologic suppression (VL\u00a0&amp;lt;50\u00a0copies\/mL), and none experienced virologic failure. Through Month 12, one (&amp;lt;1%) individual discontinued DTG\/3TC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These real-world data support the use of DTG\/3TC as a viable treatment strategy in this Australian population of individuals with HIV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh26036","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:01:37Z","timestamp":1787180497000},"source":"Crossref","is-referenced-by-count":0,"title":["ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir\/lamivudine"],"prefix":"10.1071","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-9205","authenticated-orcid":true,"given":"Daniela","family":"Eassey","sequence":"first","affiliation":[{"name":"AViiV Healthcare, Abbotsford, Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-7403","authenticated-orcid":true,"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[{"name":"BMelbourne Sexual Health Centre, Alfred Health, Melbourne, Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Koh","sequence":"additional","affiliation":[{"name":"CGladstone Road Medical Centre, Brisbane, Qld, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nolan","sequence":"additional","affiliation":[{"name":"DCentre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, WA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[{"name":"EEast Sydney Doctors, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"EEast Sydney Doctors, Sydney, NSW, Australia."},{"name":"FTaylor Square Private Clinic, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng","family":"Eu","sequence":"additional","affiliation":[{"name":"GPrahran Market Clinic, Melbourne, Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Lau","sequence":"additional","affiliation":[{"name":"HMonash Infectious Diseases, Monash Health and Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Bisshop","sequence":"additional","affiliation":[{"name":"IHoldsworth House Medical Practice, Brisbane, Qld, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kent","sequence":"additional","affiliation":[{"name":"AViiV Healthcare, Abbotsford, Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Doblado-Maldonado","sequence":"additional","affiliation":[{"name":"JViiV Healthcare, Wavre, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cowley","sequence":"additional","affiliation":[{"name":"AViiV Healthcare, Abbotsford, Vic, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bloch","sequence":"additional","affiliation":[{"name":"KHoldsworth House Medical Practice, Sydney, NSW, Australia."},{"name":"LKirby Institute, University of New South Wales, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"9903","key":"2026081919013048800_R1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease.","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"issue":"10167","key":"2026081919013048800_R2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2026081919013048800_R3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026081919013048800_R4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial.","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2026081919013048800_R5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3947\/ic.2024.0066","article-title":"Efficacy and tollerability of INI-based 2-drug regimen in virosuppressed persons living with HIV: a systematic review and meta-analysis.","volume":"56","author":"Russo","year":"2024","journal-title":"Infect Chemother"},{"issue":"9","key":"2026081919013048800_R6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort.","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med"},{"issue":"11","key":"2026081919013048800_R7","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician.","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"issue":"4","key":"2026081919013048800_R8","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review.","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"6","key":"2026081919013048800_R9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.","volume":"22","author":"Punekar","year":"2021","journal-title":"HIV Med"},{"issue":"2","key":"2026081919013048800_R10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40121-024-01103-0","article-title":"Real-world effectiveness and tolerability of dolutegravir and lamivudine 2-drug regimen in people living with HIV: systematic literature review and meta-analysis.","volume":"14","author":"Fraysse","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026081919013048800_R11","unstructured":"Australian Government: Department of Health, Disability and Ageing. Pharmaceutical Benefits Scheme (PBS). Highly specialised drugs program (community access); 2026. Available at https:\/\/www.pbs.gov.au\/browse\/section100\/highly-specialised-drugs-program-community-access [accessed 26 June 2026]"},{"key":"2026081919013048800_R12","unstructured":"US Department of Health and Human Services, Office of AIDS Research, National Institutes of Health. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2024. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combination-regimens?view=full [accessed 31 October 2025]"},{"key":"2026081919013048800_R13","unstructured":"European AIDS Clinical Society. EACS guidelines version 12.0; 2023. Available at https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines [accessed 29 June 2026]"},{"issue":"1","key":"2026081919013048800_R14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2026081919013048800_R15","unstructured":"Australian Government: Department of Health, Disability and Ageing. Pharmaceutical Benefits Scheme (PBS). Medicine status website. Dolutegravir with lamivudine. Available at https:\/\/www.pbs.gov.au\/medicinestatus\/document\/41.html [accessed 29 June 2026]"},{"key":"2026081919013048800_R16","unstructured":"Australian Government: Department of Health, Disability and Ageing. Therapeutic Goods Administration. DOVATO (ViiV Healthcare Pty Ltd). https:\/\/www.tga.gov.au\/resources\/prescription-medicines-registrations\/dovato-viiv-healthcare-pty-ltd-0 [accessed 29 June 2026]"},{"issue":"158","key":"2026081919013048800_R17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference.","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"#cr-split#-2026081919013048800_R18.1","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2025 Update of the drug resistance mutations in HIV-1. International Antiviral Society-USA. Topics in Antiviral Medicine"},{"key":"#cr-split#-2026081919013048800_R18.2","unstructured":"2025. Available at https:\/\/www.iasusa.org\/wp-content\/uploads\/2025\/03\/33-2-mutations.pdf [accessed 29 June 2026]"},{"issue":"4","key":"2026081919013048800_R19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-024-00961-y","article-title":"Two-drug regimens dolutegravir\/lamivudine and dolutegravir\/rilpivirine are effective with few discontinuations in US real-world settings: results from the TANDEM study.","volume":"13","author":"Schneider","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2026081919013048800_R20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/hiv.13699","article-title":"Real-world effectiveness and safety of switching to dolutegravir\/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.","volume":"26","author":"Pi\u00f1eiro","year":"2025","journal-title":"HIV Med"},{"key":"2026081919013048800_R21","unstructured":"The Kirby Institute, UNSW Sydney. Australian HIV observational database annual report 2022; 2022. Available at https:\/\/www.kirby.unsw.edu.au\/research\/projects\/ahod [accessed 31 October 2025]"},{"issue":"7","key":"2026081919013048800_R22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/hiv.13643","article-title":"Efficacy and safety of dolutegravir\/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.","volume":"25","author":"Katlama","year":"2024","journal-title":"HIV Med"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH26036\/1949488\/sh26036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH26036\/1949488\/sh26036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:01:38Z","timestamp":1787180498000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/23\/5\/SH26036\/275638\/ARMED-an-Australian-cohort-retrospective"}},"subtitle":[],"editor":[{"given":"Michael","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10,20]]}},"URL":"https:\/\/doi.org\/10.1071\/sh26036","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"SH26036"}}